What’s the Problem?
This FDA Recall began on Nov. 3, 2020, and affects:
- Metformin HCl Extended Release Tablets, USP 500 mg — NDC 29033-055-01 — Lot Numbers MET100201 MET100401
“The Metformin HCl Extended Release Tablets, USP 500 mg have been found to contain levels of nitrosamine impurities above the ADI limit of 96 ng/day as published in the FDA Guidance Document issued September, 2020,” FDA said. “NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests.”
The recalled metformin can be identified as an off-white oblong tablet debossed with “NM5”. These products were distributed nationwide to wholesalers.
Consumers who were prescribed any recalled metformin should talk to their doctor about exchanging the product for a safe alternative treatment.
Do not stop taking any prescription medication without consulting your physician, as doing so could result in dangerous health consequences.
Do I Have a Nostrum Metformin Class Action Lawsuit?
The Class Action Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Nostrum Metformin Lawsuits. We are handling individual litigation nationwide and currently accepting new injury and death cases in all 50 states.
If you or a loved one was injured by a recalled metformin, you should contact our law firm immediately. You may be entitled to a settlement by filing a suit and we can help.